Corcept Therapeutics (CORT) Expected to Release Quarterly Earnings on Thursday

Corcept Therapeutics (NASDAQ:CORT) is expected to release its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect Corcept Therapeutics to announce earnings of $0.0123 per share and revenue of $219.1260 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 5:00 PM ET.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.19). The firm had revenue of $164.90 million for the quarter, compared to analysts’ expectations of $185.83 million. Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.The firm’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.17 earnings per share. On average, analysts expect Corcept Therapeutics to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Corcept Therapeutics Stock Down 5.0%

Shares of CORT stock opened at $90.88 on Thursday. Corcept Therapeutics has a fifty-two week low of $28.66 and a fifty-two week high of $95.79. The stock has a market cap of $9.76 billion, a P/E ratio of 259.66 and a beta of 0.47. The business has a fifty day simple moving average of $78.85 and a 200-day simple moving average of $53.77.

Insider Transactions at Corcept Therapeutics

In other Corcept Therapeutics news, Director David L. Mahoney sold 20,000 shares of Corcept Therapeutics stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $84.53, for a total value of $1,690,600.00. Following the completion of the sale, the director owned 26,147 shares in the company, valued at $2,210,205.91. The trade was a 43.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director James N. Wilson sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $83.20, for a total transaction of $832,000.00. Following the transaction, the director directly owned 1,094,543 shares of the company’s stock, valued at $91,065,977.60. This trade represents a 0.91% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 300,000 shares of company stock valued at $22,088,050. Corporate insiders own 20.70% of the company’s stock.

Hedge Funds Weigh In On Corcept Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Pathstone Holdings LLC lifted its holdings in shares of Corcept Therapeutics by 0.8% during the 3rd quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock valued at $1,497,000 after acquiring an additional 144 shares in the last quarter. Gould Capital LLC boosted its position in Corcept Therapeutics by 50.0% during the 3rd quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 200 shares during the period. Deutsche Bank AG increased its holdings in Corcept Therapeutics by 3.4% in the 4th quarter. Deutsche Bank AG now owns 8,446 shares of the biotechnology company’s stock valued at $294,000 after purchasing an additional 279 shares in the last quarter. Advisory Services Network LLC purchased a new position in Corcept Therapeutics in the third quarter valued at about $25,000. Finally, CIBC Private Wealth Group LLC raised its position in Corcept Therapeutics by 128.5% in the third quarter. CIBC Private Wealth Group LLC now owns 770 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 433 shares during the period. 93.61% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CORT has been the topic of a number of research reports. Canaccord Genuity Group increased their price objective on shares of Corcept Therapeutics from $110.00 to $135.00 and gave the company a “buy” rating in a research note on Thursday, May 28th. Zacks Research upgraded shares of Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 4th. HC Wainwright upped their price target on shares of Corcept Therapeutics from $75.00 to $95.00 and gave the company a “buy” rating in a report on Tuesday, June 2nd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Corcept Therapeutics in a research report on Wednesday, June 24th. Finally, UBS Group set a $135.00 price target on shares of Corcept Therapeutics in a research report on Thursday, May 28th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $88.83.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.